# Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer

> **NCT00689702** · PHASE2 · UNKNOWN · sponsor: **Institute of Oncology Ljubljana** · enrollment: 43 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** cetuximab, capecitabine

## Key facts

- **NCT ID:** NCT00689702
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** 2009-04
- **Final completion:** 2013-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689702, "Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00689702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*